+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

All Ages
MALE
ID06473259

Study of Chemotherapy, Androgen-receptor Targeting Drugs, or Radiotherapy Combined With Hormone Therapy for Men With Metastatic Hormone-Sensitive Prostate Cancer in Italian Hospitals

Led by Santa Chiara Hospital · Updated on 2024-06-25

3000

Participants Needed

3

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

This observational study investigates the clinical outcomes of various treatments for metastatic hormone-sensitive prostate cancer mCSPC. Researchers are evaluating how treatments like docetaxel chemotherapy, androgen receptor targeting agents ARTAs alone or combined, and radiotherapy on the primary tumor affect patient health in everyday clinical settings. The study focuses on men diagnosed with metastatic prostate adenocarcinoma and aims to understand treatment effects in a real-world population. Participants receive one of several treatments combined with androgen deprivation therapy ADT. These include ADT plus docetaxel chemotherapy given as six 75 mgsqm intravenous courses, ADT plus an androgen receptor pathway inhibitor ARPI such as apalutamide, enzalutamide, abiraterone acetate, or darolutamide taken daily by mouth, ADT plus both docetaxel and an ARPI, or ADT combined with radical radiotherapy directed at the primary tumor. Treatments reflect normal clinical practice or expanded access programs started between 2015 and 2027. Throughout the study, researchers collect clinical data from participants medical records during routine care. The main outcome measured is progression-free survival, tracking time from treatment start until disease progression or death, assessed up to 120 months. Overall survival is a secondary measure. The study involves long-term follow-up to monitor how these treatments impact disease progression and patient survival over time.

CONDITIONS

Brief Title

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

Research Team

O

Orazio Caffo, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here